Subcutaneous Injection

CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United States, with no new safety signals reported.

Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research letter published in JAMA Oncology.

The FDA has issued a complete response letter to AbbVie regarding its new drug application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

Clinical-stage biopharmaceutical company Immunovant Inc. announced it has reached agreement with the FDA to initiate a phase 3 study of batoclimab in patients with myasthenia gravis in the first half of the year.

Aimovig appeared safe and effective for treating migraine with and without history of aura, according to results of a secondary analysis of randomized clinical trials published in JAMA Neurology.

ATLANTA – Regulations governing the use of injections in the optometric practice vary from state to state.